Reaping in due season? R&D trends and novel drug launches
This article was originally published in Scrip
In the fashion world, hemlines drop at the first hint of a recession, but seasons in pharmaceutical R&D are more reminiscent of those in the A Game of Thrones’ mythical land of Westeros – they change very slowly.
You may also be interested in...
INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.
AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.
A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.